Clinical trials in Leiden – page 71

1 938 clinical trials in Leiden, The Netherlands across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Leiden at a glance

1 938

clinical trials

Research sites4

Quick filters

1 938 trials in Leiden

Open in trial search

Eosinophilic oesophagitis

Not yet recruiting

Dupilumab Maintenance Dose Optimization in Adults with Eosinophilic Esophagitis: A Randomized Controlled Non‑Inferiority Study

Registered drugNo placebo

Dupilumab Maintenance Dose Optimization in Adults with Eosinophilic Esophagitis: A Randomized Controlled Non‑Inferiority Study

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Dupilumab
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cenegermin
Sponsor:Dompe' Farmaceutici S.p.A.

Contact Research Centre

Diffuse large B-cell lymphoma

Not yet recruiting

Epcoritamab plus rituximab versus rituximab alone in elderly, frail or unfit patients with newly diagnosed diffuse large B‑cell lymphoma

Registered drugNo placebo

Epcoritamab plus rituximab versus rituximab alone in elderly, frail or unfit patients with newly diagnosed diffuse large B‑cell lymphoma

Registered drugNo placebo

The Netherlands

Participants:65+ years
Substances:Epcoritamab
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Acute myeloid leukaemia+2

Not yet recruiting

Safety and tolerability study of S-241656 with posaconazole in patients with AML, MDS/AML or CMML

Registered drugNo placebo

Safety and tolerability study of S-241656 with posaconazole in patients with AML, MDS/AML or CMML

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Posaconazole
Sponsor:Institut De Recherches Internationales Servier IRIS

Contact Research Centre

Post-traumatic stress disorder

Not yet recruiting

Study of MDMA hydrochloride therapy in adolescents aged 16‑18 with treatment‑resistant post‑traumatic stress disorder

InvestigationalNo placebo

Study of MDMA hydrochloride therapy in adolescents aged 16‑18 with treatment‑resistant post‑traumatic stress disorder

InvestigationalNo placebo

The Netherlands

Participants:0–17 years
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Small cell lung cancer limited stage

Not yet recruiting

Durvalumab after chemoradiation for patients with limited‑stage small cell lung cancer: a randomized trial of high‑dose versus standard thoracic radiation

Registered drugNo placebo

Durvalumab after chemoradiation for patients with limited‑stage small cell lung cancer: a randomized trial of high‑dose versus standard thoracic radiation

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Norwegian University Of Science And Technolology

Contact Research Centre

Heart failure with reduced ejection fraction

Not yet recruiting

Evaluating the efficacy and safety of CRD-4730 in patients with heart failure with reduced ejection fraction

Investigational

Evaluating the efficacy and safety of CRD-4730 in patients with heart failure with reduced ejection fraction

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:CRD-4730
Sponsor:Cardurion Pharmaceuticals Inc.

Contact Research Centre

Barth syndrome

Not yet recruiting

Efficacy and Safety of Daily Subcutaneous Elamipretide Trihydrochloride Injections in Patients with Barth Syndrome (Phase 3b/4 Randomized Trial)

Investigational

Efficacy and Safety of Daily Subcutaneous Elamipretide Trihydrochloride Injections in Patients with Barth Syndrome (Phase 3b/4 Randomized Trial)

Investigational

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Stealth Biotherapeutics Inc.

Contact Research Centre

Gastric cancer+1

Not yet recruiting

Capecitabine drug combination in perioperative treatment for patients with gastric and esophageal cancer

Registered drugNo placebo

Capecitabine drug combination in perioperative treatment for patients with gastric and esophageal cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Squamous cell carcinoma of the oral cavity+1

Not yet recruiting

Study of neoadjuvant intratumoral ipilimumab combined with systemic nivolumab in patients with locally advanced resectable oral cavity squamous cell carcinoma

Registered drugNo placebo

Study of neoadjuvant intratumoral ipilimumab combined with systemic nivolumab in patients with locally advanced resectable oral cavity squamous cell carcinoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ipilimumab
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Adenomatous polyposis coli

Not yet recruiting

Study of REC-4881 in Adults with Familial Adenomatous Polyposis to Assess Safety and Efficacy

Investigational

Study of REC-4881 in Adults with Familial Adenomatous Polyposis to Assess Safety and Efficacy

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:TAK-733
Sponsor:Recursion Pharmaceuticals Inc.

Contact Research Centre

Pleural mesothelioma

Not yet recruiting

Reducing Toxicity of Dual PD‑1 and CTLA‑4 Checkpoint Therapy in Pleural Mesothelioma Patients with Ustekinumab (anti‑p40)

Registered drugNo placebo

Reducing Toxicity of Dual PD‑1 and CTLA‑4 Checkpoint Therapy in Pleural Mesothelioma Patients with Ustekinumab (anti‑p40)

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ustekinumab
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Leiden

What the registry says about research in the country

01 Infectious Diseases Research

Innovative studies focusing on viral infections including trials evaluating vaccines against yellow fever, influenza, and mpox. Research includes assessment of antibody responses and vaccine effectiveness in different populations.

Influenza vaccine efficacy in elderly
Yellow fever prophylaxis
Mpox booster vaccination

Particular emphasis on preventive strategies and immune response evaluation.

02 Neurological Studies

Comprehensive research targeting neurological conditions, including investigations into Parkinson's disease treatments and neural response patterns. Studies examine innovative therapeutic approaches.

Parkinson's Disease treatments
CNS response analysis
Cerebral Amyloid Angiopathy

Focus on developing targeted therapies and understanding brain mechanisms.

03 Cancer and Chronic Conditions

Advanced research in oncology and chronic diseases, including studies on gastric cancer imaging and T-cell lymphoma treatments. Investigations into kidney disease management.

Advanced solid tumors
Gastric cancer diagnosis
Chronic kidney disease

Emphasis on innovative diagnostic techniques and treatment approaches.

Back to the Netherlands All countries